Category - Developments

Developments

Titan Pharma’s Probuphine implant to treat OUD gains media attention in Canada

Television station, CFJC, of Kamloops, British Columbia, Canada has produced a segment about the first patient in the region to receive Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphineas a new...

April 18, 2019

Developments

Canopy Growth secures right to acquire U.S. cannabis operator Acreage Holdings

Canopy Growth (TSX:WEED; NYSE:CGC) entered a complex arrangement to acquire Acreage Holdings (CSE:ACGR; OTC:ACRGF; FSE:0ZV) when cannabis production and sale becomes federally legal in the U.S.

April 18, 2019

Developments

Canopy Growth acquires Spanish licensed cannabis producer

Canopy Growth (TSX:WEED; NYSE:CGC) completed an all-cash acquisition of Spain-based licensed cannabis producer, Cáñamo y Fibras Naturales, (Cafina). The acquisition lays the foundation for Canopy to expand its European...

April 16, 2019

Developments

Profound Medical announces first-of-its-kind TULSA-PRO installation

Profound Medical (TSX:PRN; OTCQX:PRFMF) announced the first prostate cancer treatment using a first-of-its-kind TULSA-PRO installation in Trier, Germany. The installation combines Profound’s TULSA-PRO system with...

April 16, 2019

Developments

IntelGenx files U.S. patent application for oil-based active ingredients

IntelGenx (TSX-V:IGX; OTCQX:IGXT) filed a new non-provisional patent application with the U.S. Patent and Trademark Office, covering a newly developed platform that enables incorporation of oil-based (lipophilic) active...

April 16, 2019

Developments

Albireo Pharma presents positive Phase 2 data for pediatric cholestasis candidate

Albireo Pharma (NASDAQ:ALBO) presented positive Phase 2 data for its drug candidate, A4250, at The International Liver Congress 2019. A4250 is being developed to treat rare pediatric cholestatic liver diseases, where...

April 16, 2019

Developments

MediciNova to conduct Phase 2b/3 trial for ALS candidate

MediciNova (NASDAQ:MNOV) received FDA approval to conduct a Phase 2b/3 clinical trial of MN-166 in amyotrophic lateral sclerosis (ALS) patients. MN-166, or ibudilast, suppresses pro-inflammatory cytokines, promotes...

April 16, 2019

Developments

TG Therapeutics gets FDA’s orphan drug designation for umbralisib

TG Therapeutics (NASDAQ:TGTX) received the FDA’s orphan drug designation for its phosphoinositide-3-kinase delta inhibitor, umbralisib, for the treatment of patients with marginal zone lymphoma (MZL). MZL is a slow...

April 15, 2019

Developments

Arrowhead Pharma’s RNAi candidate gets FDA clearance for Phase 2/3 trial

Arrowhead Pharma (NASDAQ:ARWR) received FDA clearance to proceed with its adaptive Phase 2/3 trial evaluating ARO-AAT in patients with alpha-1 antitrypsin (AAT) deficiency-associated liver disease. AAT deficiency is a...

April 15, 2019

Developments

Titan Pharma’s Probuphine now in use across Canada

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant for opioid use disorder is now being used in patients across Canada. Approved by Health Canada in April 2018, Probuphine is the only subdermal implant designed to...

April 15, 2019

Category - Developments

Subscribe